INSIGHTS
Perspectives at the intersection of science, execution and capital.
Thoughts on development, regulation, investment and AI × biotech from our work, our reading and the wider conversation across ecosystems.
ON LINKEDIN
Recent perspectives, shorter form.
A curated selection of recent posts from our LinkedIn presence. Observations on biotech development, AI × biotech and the wider ecosystem. Follow Cellvanta for the full stream.
INVESTMENT & RISK
When flow cytometry becomes the regulatory decision-maker.
For cell and gene therapies, regulators no longer ask whether you have flow data, they ask whether it's fit for purpose. The gap between research-grade flow and decision-grade flow is where many CMC packages wobble, and increasingly where investors are taking notice.
CMC STRATEGY
Flow cytometry that holds up under CMC and regulatory pressure.
Marker selection, defensible gating, variability control and matrixed potency are practical considerations that determine whether a flow cytometry panel survives scale-up. A view on designing assays that don't just look good in development, but support confident decisions across CMC and comparability.
CMC STRATEGY
Potency in cell therapy is a strategy, not an assay.
High-dimensional flow cytometry can capture functional heterogeneity, MOA signatures and batch-to-batch consistency — but only when panels are designed with biology, feasibility and regulatory alignment in mind. A view on treating potency as a strategy from first clinical batch onward.